Autoantibodies in polymyositis and dermatomyositis

Current Rheumatology Reports

Volumn 15, Issue 6, 2013, Pages

  Ghirardello, Anna ^a   Bassi, Nicola ^a   Palma, Lavinia ^a   Borella, Elisabetta ^a   Domeneghetti, Marta ^a   Punzi, Leonardo ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoantibodies; Autoimmune myositis; Dermatomyositis; Inflammatory myopathies; Myositis associated autoantibodies; Myositis specific auto antibodies; Polymyositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINOACYL TRNA SYNTHETASE AUTOANTIBODY; AUTOANTIBODY; AUTOANTIGEN; B LYMPHOCYTE ANTIGEN; BIOLOGICAL MARKER; ENZYME; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; MDA5 AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; NUCLEAR HELICASE PROTEIN MI 2; NUCLEAR HELICASE PROTEIN MI 2 AUTOANTIBODY; NUCLEAR MATRIX PROTEIN NXP2; NUCLEAR MATRIX PROTEIN NXP2 AUTOANTIBODY; NUCLEAR PROTEIN; RO52 ANTIBODY; SIGNAL RECOGNITION PARTICLE; SIGNAL RECOGNITION PARTICLE AUTOANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME AUTOANTIBODY; SUMO 1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA AUTOANTIBODY; UNCLASSIFIED DRUG; CHD4 PROTEIN, HUMAN; HISTIDINE TRANSFER RNA LIGASE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER RISK; CARCINOGENESIS; CELLULAR IMMUNITY; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ACTIVITY; ENDOPLASMIC RETICULUM STRESS; ETHNICITY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; INFLAMMATION; JUVENILE DERMATOMYOSITIS; MUSCLE BIOPSY; MUSCLE REGENERATION; MUSCLE WEAKNESS; MYOSITIS; NECROTIZING AUTOIMMUNE MYOSITIS; NEOPLASM; POLYMYOSITIS; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUMOYLATION; UBIQUITINATION; UPREGULATION; BLOOD; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; REVIEW; SKELETAL MUSCLE;

AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; DERMATOMYOSITIS; HISTIDINE-TRNA LIGASE; HUMANS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; REGENERATION; SIGNAL RECOGNITION PARTICLE;

EID: 84876126473     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0335-1     Document Type: Article

References (90)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first part). N Engl J Med. 1975;292:344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second part). N Engl J Med. 1975;292:403-7.
3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-82. (Pubitemid 37159295)
4. Mathiesen PR, Zak M, Heilin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol. 2010;28:782-9.
5. • Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol. 2011;37:226-42. In this review article, distinct histopathological features and pathological mechanisms of the main types of inflammatory and autoimmune myopathies are described in detail.
6. Hengstman GJD, Brouwer R, Vree Egberts WTM, Jougen PJH, Seelig HP, Van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients; myositis specific autoantibodies aid in the differential diagnosis of idiopathic inflammatory myopathies. J Neurol. 2002;249:69-75. (Pubitemid 34119026)
7. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10:333-40.
8. Vincze M, Molnar PA, Tumpek J, Szollosi L, Gyetvai A, Kapitani A, et al. An unusual association: anti-Jo-1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol. 2010;29:811-4.
9. Sugie K, Tonomura Y, Ueno S. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Int Med. 2011;51:799-802.
10. Nakajima A, Yoshino K, Soejima M, Kawaguchi Y, Satoh T, Kuwana M, et al. High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatol Int. 2012;32:2057-61.
11. Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity. 2005;38:73-8. (Pubitemid 40515006)
12. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, et al. Anti-Mi-2 autoantibodies. Autoimmunity. 2005;38:79-83. (Pubitemid 40515007)
13. Hengstman GJD, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis. 2006;65:242-5. (Pubitemid 43132001)
14. Brouwer R, Hengstmam GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibodies profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60:116-23. (Pubitemid 32102201)
15. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65:1635-8. (Pubitemid 44799678)
16. Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Gorza L, Doria A. Cutting edge issues in polymyositis. Clin Rev Allergy Immunol. 2011;41:179-89.
17. • Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25-34. This retrospective study provides clues to the mucocutaneous and systemic features specifically associated with anti-MDA5 antibodies in adult patients with DM.
18. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:R209.
19. •• Mammen AL, Chung T, Christopher- Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713-21. The target antigen of anti-200/100kDa antibodies was identified as the 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Moreover, it was shown that statin exposure induces HMGCR overexpression in muscle fibers in vitro, and HMGCR is expressed at high levels in regenerating muscle fibers from anti-HMGCR-positive patients.
20. Hengstman GJD, van Brenk L, Vree Egberts WTM, Van der Kooij EL, Borm GF, Padberg GWAM, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol. 2005;252:534-7. (Pubitemid 40768168)
21. Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford). 2008;47:1539-42.
22. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol. 2008;20:675-80.
23. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019-38. (Pubitemid 20370993)
24. • Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2012;3:363-73. An interesting overview of the diagnosis, classification, and current treatment approach of overlap syndromes is presented.
25. Christopher-Stine L, Robinson DR, Wu CC, Mark EJ. Case 37-2012: a 21-year-old man with fever, arthralgias, and pulmonary infiltrates. N Eng J Med. 2012;367:2134-46.
26. Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39:217-21. (Pubitemid 43879034)
27. Harvier B, Wallaert B, Machulla E, Adoue D, Lauque D, Audrain M, et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49:972-6.
28. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633-8.
29. • Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Dankó K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91:206-11. This retrospective multicenter study of a large European myositis cohort confirmed the association of anti-PL-7 antibodies with the major clinical features of antisynthetase syndrome. In addition, pericardial effusion was found associated with anti-PL-7 antibody. This novel finding needs to be further studied.
30. •• Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238-47. Intriguingly, anti-ARS antibodies were found in about 7 % of 198 consecutive patients with idiopathic interstitial pneumonias, thus giving a relevant contribution to the definition of "idiopathic" interstitial lung disease.
31. Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum. 2002;46:1885-93. (Pubitemid 34774521)
32. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;28:11-23.
33. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38:973-9.
34. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391-8.
35. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger Jr TA, Reveille JD, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60:2499-504.
36. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010;49:2370-4.
37. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433-8. (Pubitemid 47255925)
38. Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66:1345-9. (Pubitemid 47492479)
39. Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-α antibodies-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies. Rheumatology (Oxford). 2012;51:1508-13.
40. Römisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther. 2006;8:R39.
41. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48:594-5.
42. Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol. 2009;19:156-64.
43. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50:209-15. (Pubitemid 38084306)
44. Liewluck T. Comment on: clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford). 2009;48:90-1.
45. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by Melanoma Differentiation-Associated Gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2009;60:2193.
46. • Nakashima R, Imura Y, Kabayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433-40. The autoantigen recognized by anti-CADM-140 antibody was identified as the interferon induced with helicase C domain protein 1 (IFIH1), also known as MDA5 protein.
47. • Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation- associated gene 5 antibody. Arthritis Care Res. 2012;64:1602-10. The specificity and prognostic value of anti-MDA5 antibody in Chinese DM patients is established, also demonstrating that antibody levels are helpful in predicting ILD prognosis and response to treatment.
48. Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Mod Virol. 2010;20:4-22.
49. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-9.
50. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682-9. (Pubitemid 44737181)
51. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura T, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46:25-8. (Pubitemid 44932779)
52. • Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, MartInez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis. A systematic review and meta-analysis. Arthritis Rheum. 2012;64:523-32. Based on a systematic review and meta-analysis study, the authors assessed the diagnostic value of anti-p155 testing for cancer-associated myositis.
53. • Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol. 2010;22:627-32. This interesting review highlights recent advances in the relationship between malignancy and myositis, and proposes the best approach for cancer diagnosis in myositis patients.
54. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis. 2012;71:993-6.
55. •• Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513-22. In this elegant study, the immunoreactivity and clinical associations of the autoimmune response against TIF1 family proteins were extensively analyzed in a large cohort of DM patients.
56. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarsai T. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis (abstract). Arthritis Rheum. 2006;54:S518. (Pubitemid 44737181)
57. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726-33.
58. Gunawardena H, Wedderbun LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60:1807-14.
59. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36:2547-51.
60. Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007;18:1701-9. (Pubitemid 46717552)
61. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710-3.
62. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14:R97.
63. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132-7. (Pubitemid 47502761)
64. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis. 2009;68:1621-5.
65. • Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384:128-34. An unlabeled protein immunoprecipitation assay applied to the identification of anti-SAE antibody is described in detail.
66. Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis. 2013;72:151-3.
67. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757-66.
68. •• Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64:269-72. A community-based study assessing the high specificity of anti-HMGCR antibodies for statin-associated autoimmune myopathy requiring immunoppressive therapy.
69. Franceschini F, Cavazzana I, Generali D, Quinzanini M, Ghirardello A, Doria A, et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol. 2002;29:1393-7. (Pubitemid 34755602)
70. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78. (Pubitemid 47422690)
71. Vancsa A, Gergely L, Ponyi A, Nemeth J, Szodoray P, Danko K. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical associations: retrospective study of 169 patients. J B Spine. 2010;77:125-30.
72. Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37:1000-9.
73. • Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012;41:890-9. The clinical relevance of anti-Ro52 antibodies in anti-Jo 1-positive patients with autoimmune myositis was elucidated. Anti-Ro52 antibodies were significantly associated with more severe interstitial lung disease, myositis and joint involvement, and poorer long-term outcome compared with anti-Jo1-positive patients without anti-Ro52 antibodies.
74. Ghirardello A, Bendo R, Rampudda ME, Bassi N, Zampieri S, Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev. 2009;8:645-9.
75. Rönnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Frank-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9:58-61.
76. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125-31. (Pubitemid 47502760)
77. • Benveniste O, Drouot L, Joven F, Charvel J, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;67:1961-71. Anti-SRP autoantibody levels reflect the degree of myolysis and response to treatment in necrotizing myopathies.
78. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strenght in anti-3-hydroxy-3-methyl-glutaryl-coenzyme A-reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64:4087-93.
79. Casciola-Rosen L, Nagaraju K, Plots P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201:591-601. (Pubitemid 40289549)
80. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009;60:3784-93.
81. Zampieri S, Biral D, Adami N, Ghirardello A, Rampudda M, Tonello M, et al. Expression of myositis specific autoantigens during postnatal myogenesis. Neurol Res. 2008;30:145-8. (Pubitemid 351768833)
82. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24:602-8.
83. • Zampieri S, Doria A, Adami N, Biral N, Vecchiato M, Savastano S, et al. Subclinical myopathy in patients affected with early stage colorectal cancer at disease onset: evidence from skeletal muscle biopsies. Neurol Res. 2010;32:20-5. Skeletal muscle from patients with recent-onset cancer show histopathologic myopathic features similar to those observed in muscle of patients with cancer-associated myositis.
84. Zampieri S, Valente M, Adami N, Corbianco S, Doria A, Biral D, et al. Subclinical myopathy in patients affected with early stage colorectal cancer at disease onset: No evidence of inflammatory cells infiltration in the skeletal muscle biopsies harvested during diagnostic laparoscopy. Basic Appl Myol. 2009;19:247-52.
85. Zampieri S, Valente M, Adami N, Biral N, Ghirardello A, Rampudda M, et al. Polymyositis, dermatomyositis and malignancy: A further intriguing link. Autoimmun Rev. 2010;9:449-53.
86. Lundberg IE, Helmers SB. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity. 2010;43:239-43.
87. Eloranta M, Barbasso Helmers S, Ulfgren A-K, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112-24. (Pubitemid 47502759)
88. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum response in autoimmune myositis. Arthritis Rheum. 2005;52:824-35. (Pubitemid 40852891)
89. Tarricone E, Ghirardello A, Zampieri A, Rampudda ME, Doria A, Gorza L. Cell stress-response in skeletal muscle myofibers. Ann NY Acad Sci. 2006;1069:472-6. (Pubitemid 43989891)
90. •• Vitadello M, Doria A, Tarricone E, Ghirardello A, Gorza L. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res Ther. 2010;12:R52. In myositis patients, an endoplasmic reticulum-stress response occurs, mainly characterized by the upregulation of Grp94 and Grp75 chaperone proteins in regenerating myofibers.